Navigation Links
Genomic Profiling of Breast Cancers a Better Treatment Tool
Date:4/1/2008

Findings point to personalized therapies that help predict disease recurrence

TUESDAY, April 1 (HealthDay News) -- Determining the genetic profile of a breast tumor, along with an assessment of a patient's clinical characteristics, can help predict prognosis and guide treatment choices, a Duke University study concludes.

"Our goal is to treat patients on a more individualized basis, matching the right drugs with the right patients," Dr. Anil Potti, an oncologist and researcher in the Duke Comprehensive Cancer Center and Duke's Institute for Genome Sciences & Policy, said in a prepared statement.

"The combination of these two methods, one of which uses the clinical description of a patient's breast cancer and the other which looks at the gene expression at a molecular level in a patient's tumor, may allow us to do that with unprecedented accuracy. This represents a robust approach to personalizing treatment strategies in patients suffering from breast cancer," Potti said.

The team examined almost 1,000 breast tumors and corresponding patient data and used a computerized system called Adjuvant! to assess clinical characteristics and make predictions of recurrence. The researchers then compared gene expression in the tumor samples and were able to identify specific genomic patterns among patients with aggressive cancers and those with cancers less likely to recur.

"We knew from previous studies that Adjuvant! tends to overestimate disease recurrence in younger patients. We hypothesized that genomic profiling could be a complementary tool that would more precisely define clinical outcomes and could also help to aid in selecting the right drug for a given patient," Potti said.

Not only did their method identify patients at high risk for cancer recurrence, it specified the degree of that risk. For example, they could predict that a patient had a 90 percent risk of recurrence.

"This is important, because with this data, we might decide to treat this person more aggressively even than someone else who is considered 'high risk' but may have only a 60 percent likelihood of recurrence," Potti said. "Moreover, we can identify specific options for chemotherapy in such patients as well, by correlating gene expression in a tumor with its response, or non-response, to certain chemotherapies."

The study was published in the April 2 issue of the Journal of the American Medical Association.

This study "demonstrates the potential value of using microarray-based gene signatures to refine outcome predictions," Chiang-Ching Huang and Markus Bredel, of the Feinberg School of Medicine at Northwestern University in Chicago, wrote in an accompanying editorial.

"In an attempt to tailor risk estimation, these investigators shy away from pure metagene predictors but instead focus on genes with mechanistic implication in breast cancer. Because these genes represent potential targets for specific molecular therapy, this approach represents an advance in the changing landscape of oncology toward individualized patient management," they wrote.

More information

The American Cancer Society has more about breast cancer.



-- Robert Preidt



SOURCES: Duke University, news release; JAMA/Archives journals, news release, both April 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genomic Profiling of Breast Cancers a Better Treatment Tool
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: